Core Framework & Diagram How Does the Immune System Recognize Cancer Cells?
7 月 14, 20261 Min Read How Do T Cells Kill Cancer Cells?
7 月 14, 2026Your body produces potential cancer cells every day — here's how the immune system finds them
—— Immune surveillance: a daily cancer-prevention operation happening right now, completely undetected by you.
I. Your body produces potential cancer cells every day — you're completely unaware
This is a biological reality that surprises most people, but it's entirely true: your body generates cells with DNA mutations every single day, giving them the potential to develop toward cancer.
The human body undergoes approximately 370 billion cell divisions daily, each involving replication of roughly 6 billion base pairs of DNA. Even with precise DNA repair mechanisms, each replication still produces a small number of errors. Add DNA damage from UV radiation, environmental chemicals, and reactive oxygen species — every person generates thousands of DNA damage events daily, some causing mutations, a few potentially affecting proto-oncogenes or tumor suppressor genes.
So why don't most people develop new cancers every day? Two reasons. First, cells have powerful DNA damage repair systems — most mutations are fixed before the immune system even detects them. Second, mutated cells must overcome a series of molecular checkpoints (tumor suppressor gene guardians) to actually acquire uncontrolled proliferation capacity.
But the third line of defense is the immune system. Even if a cell breaks through the first two lines and starts showing abnormal characteristics, patrolling immune cells — especially NK cells and CD8+ T cells — can still recognize and eliminate it before it forms a real tumor. This 'third line of defense' is immune surveillance.
2. NK cells' daily anti-cancer work: two signals, one decision
NK cells are the most important first-line sentinels of immune surveillance. Understanding how NK cells recognize early cancer cells requires understanding the core judgment they make: is this cell normal, or has something gone wrong?
This judgment is made by simultaneously checking two categories of signals.
Category one: inhibitory signals — proof of being 'one of us'
Normal cells highly express MHC-I molecules on their surface. MHC-I binding to NK cell surface inhibitory KIR receptors sends a 'this is a normal human cell, don't attack' signal. As long as this signal is adequate, NK cells hold back.
Category two: activating signals — the 'something's wrong with me' distress call
When a cell experiences DNA damage, oxidative stress, or begins malignant transformation, it upregulates a class of proteins called NKG2D ligands (MICA, MICB, ULBP family) on its surface. These molecules are detected by NK cell surface NKG2D receptors, generating an activation signal.
NK cells' decision is a combined assessment of both signal categories: strong inhibitory signal (normal MHC-I) + weak activating signal (no stress ligands) → normal cell, pass. Weakened inhibitory signal (MHC-I downregulated — a common feature of cancer cells, which do this to evade T cell recognition) or activating signal present (stress ligands appearing) → abnormal cell, engage.
Cancer cells often satisfy both conditions simultaneously: during malignant transformation, MHC-I expression frequently decreases (helping evade T cells), while DNA damage and abnormal cellular metabolism upregulate NKG2D ligands. This dual signal overlap lets NK cells reliably identify early cancer cells.
Research shows NK cells may participate in clearing thousands of potentially dangerous cells daily. Most of the time, this defensive battle ends without you ever knowing. A prospective cohort study following over 3,600 participants for eleven years (Imai et al., Lancet, 2000) found that people with lower baseline NK cell activity had significantly higher cancer diagnosis risk during follow-up — the most direct population evidence for NK cells' cancer prevention function.
3. CD8+ T cell precision cancer surveillance: recognizing neoantigens
If NK cells use 'universal abnormal signals' to identify early cancer cells, CD8+ T cell recognition is more precise — relying on neoantigens unique to cancer cells.
Cancer cells, in generating gene mutations, produce mutant proteins that never appeared in normal cells. After these mutant proteins are degraded into peptides inside the cell, they're presented on the cell surface via MHC-I molecules. To CD8+ T cells, these 'mutant peptide-MHC-I' complexes are abnormal signals — the TCR can recognize this peptide characteristic absent in normal cells, then kill cells carrying it.
The elegance of this process: it can distinguish 'cancer cells carrying a specific mutation' from 'surrounding normal cells' — because normal cells simply don't have this mutant protein and won't present this peptide, so they won't be attacked erroneously.
This is why 'neoantigens' are so critically important in tumor immunology. The higher a tumor's mutational burden (more mutations in the tumor genome, more neoantigens produced), the greater the immune system's opportunity to recognize and kill that tumor. This also explains why melanoma (extremely high mutational burden from UV radiation DNA damage) and smoking-associated lung cancer (similarly high mutational burden) show the highest response rates to PD-1 immune checkpoint therapy among all tumor types — more neoantigens means more 'targets' for T cells to attack.
4. Tumor evasion: how cancer cells defeat immune surveillance
Immune surveillance is powerful but not impenetrable. Cancer cells, over a long evolutionary process (sometimes years to decades), gradually acquire various abilities to evade immune surveillance through Darwinian natural selection — a process called immune evasion.
Downregulating MHC-I expression
MHC-I is the 'display window' CD8+ T cells use to identify cancer cells. If cancer cells, through genetic mutation or epigenetic changes, reduce MHC-I expression, CD8+ T cells lose their ability to see targets. This MHC-I downregulation is very common in many solid tumors (in some tumors, fifty to sixty percent of cells show reduced MHC-I expression) — the most direct tumor evasion of adaptive immune responses.
But as noted, MHC-I downregulation triggers NK cell attack. Tumor cells often simultaneously evolve mechanisms to suppress NK cells: high expression of non-classical MHC-I subtypes (like HLA-E) that can bind NK cell inhibitory receptors. Even if classical MHC-I is reduced, NK cells are still fooled into not acting.
Expressing PD-L1
When cancer cells express PD-L1, it binds to T cell surface PD-1 receptors, sending T cells a 'brake' signal causing them to enter an exhausted state. This is exactly why PD-1/PD-L1 checkpoint inhibitors work — by blocking this 'brake' signal, letting T cells reactivate to attack tumors.
Secreting TGF-β and IL-10, recruiting Treg cells
Cancer cells secrete TGF-β and IL-10 and recruit Treg cells into the tumor microenvironment, building an overall immunosuppressive local environment where any effector T cells entering the tumor struggle to maintain activity.
5. Immune surveillance, cancer risk, and age: why cancer incidence rises sharply after fifty
Cancer incidence rises exponentially with age — one of tumor epidemiology's most robust findings. The cancer risk at fifty is approximately five to ten times that at thirty; at seventy, it may be fifty-fold or more higher than at thirty.
Traditionally this is attributed to mutation accumulation: older age means more cell divisions, more DNA replication errors, higher probability of enough key mutations occurring by chance. This explanation is correct but incomplete.
Declining immune surveillance capacity is an equally important other half of the explanation.
With aging: NK cell activity falls approximately fifteen to twenty percent per decade, with declining sensitivity to detecting MHC-I-downregulated cells and declining killing efficiency; CD8+ T cell library diversity shrinks, with fewer T cell clones capable of recognizing specific neoantigens; chronic inflammation rises (inflammaging), providing a more favorable microenvironment for tumor growth; regulatory T cell (Treg) functional abnormalities may exacerbate immunosuppression in tumor microenvironments.
This means: even without any change in mutation generation rate, after forty the immune system's efficiency at clearing early cancer cells is declining, and the proportion of abnormal cells that slip through is rising. 'Mutation accumulation' and 'weakened immune surveillance' working together synergistically drive the exponential rise in cancer incidence.
From this perspective, any action that maintains NK cell activity (regular exercise) and reduces chronic inflammation (low-inflammation lifestyle, adequate sleep) isn't just 'staying healthy' — it's genuinely maintaining your daily cancer prevention system. This lens provides a more profound, more specific reason for the health recommendations we're already familiar with.
Frequently Asked Questions